Rahul R Parikh1,2, Michael L Grossbard3, B Lee Green4, Louis B Harrison5, Joachim Yahalom6. 1. Department of Radiation Oncology, Mount Sinai Beth Israel Medical Center, Mount Sinai Health System, New York, New York. 2. Department of Radiation Oncology, Mount Sinai Roosevelt Hospital, Mount Sinai Health System, New York, New York. 3. Division of Hematology-Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, New York. 4. Division of Population Sciences, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 5. Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 6. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
BACKGROUND: The association between insurance status and outcomes has not been well established for patients with Hodgkin lymphoma (HL). The purpose of this study was to examine the disparities in overall survival (OS) by insurance status in a large cohort of patients with HL. METHODS: The National Cancer Data Base (NCDB) was used to evaluate patients with stage I to IV HL from 1998 to 2011. The association between insurance status, covariables, and outcomes was assessed in a multivariate Cox proportional hazards model. Survival was estimated with the Kaplan-Meier method. RESULTS: Among the 76,681 patients within the NCDB, 45,777 patients with stage I to IV HL were eligible for this study (median follow-up, 6.0 years). The median age was 39 years (range, 18-90 years). The insurance status was as follows: 3247 (7.1%) were uninsured, 7962 (17.4%) had Medicaid, 30,334 (66.3%) had private insurance, 3746 (8.2%) had managed care, and 488 (1.1%) had Medicare. Patients with an unfavorable insurance status (Medicaid/uninsured) were at a more advanced stage, had higher comorbidity scores, had B symptoms, and were in a lower income/education quartile (all P < .01). These patients were less likely to receive radiotherapy and start chemotherapy promptly and were less commonly treated at academic/research centers (all P < .01). Patients with unfavorable insurance had a 5-year OS of 54% versus 87% for those favorably insured (P < .01). When adjustments were made for covariates, an unfavorable insurance status was associated with significantly decreased OS (hazard ratio, 1.60; 95% confidence interval, 1.34-1.91; P < .01). The unfavorable insurance status rate increased from 22.8% to 28.8% between 1998 and 2011. CONCLUSIONS: This study reveals that HL patients with Medicaid and uninsured patients have outcomes inferior to those of patients with more favorable insurance. Targeting this subset of patients with limited access to care may help to improve outcomes. Cancer 2015;121:3435-43.
BACKGROUND: The association between insurance status and outcomes has not been well established for patients with Hodgkin lymphoma (HL). The purpose of this study was to examine the disparities in overall survival (OS) by insurance status in a large cohort of patients with HL. METHODS: The National Cancer Data Base (NCDB) was used to evaluate patients with stage I to IV HL from 1998 to 2011. The association between insurance status, covariables, and outcomes was assessed in a multivariate Cox proportional hazards model. Survival was estimated with the Kaplan-Meier method. RESULTS: Among the 76,681 patients within the NCDB, 45,777 patients with stage I to IV HL were eligible for this study (median follow-up, 6.0 years). The median age was 39 years (range, 18-90 years). The insurance status was as follows: 3247 (7.1%) were uninsured, 7962 (17.4%) had Medicaid, 30,334 (66.3%) had private insurance, 3746 (8.2%) had managed care, and 488 (1.1%) had Medicare. Patients with an unfavorable insurance status (Medicaid/uninsured) were at a more advanced stage, had higher comorbidity scores, had B symptoms, and were in a lower income/education quartile (all P < .01). These patients were less likely to receive radiotherapy and start chemotherapy promptly and were less commonly treated at academic/research centers (all P < .01). Patients with unfavorable insurance had a 5-year OS of 54% versus 87% for those favorably insured (P < .01). When adjustments were made for covariates, an unfavorable insurance status was associated with significantly decreased OS (hazard ratio, 1.60; 95% confidence interval, 1.34-1.91; P < .01). The unfavorable insurance status rate increased from 22.8% to 28.8% between 1998 and 2011. CONCLUSIONS: This study reveals that HL patients with Medicaid and uninsured patients have outcomes inferior to those of patients with more favorable insurance. Targeting this subset of patients with limited access to care may help to improve outcomes. Cancer 2015;121:3435-43.
Authors: Yoland F Philpotts; Xiaoyue Ma; Michaela R Anderson; May Hua; Matthew R Baldwin Journal: J Am Geriatr Soc Date: 2019-08-26 Impact factor: 5.562
Authors: Matthew R Baldwin; Jessica L Sell; Nina Heyden; Azka Javaid; David A Berlin; Wendy C Gonzalez; Peter B Bach; Mathew S Maurer; Gina S Lovasi; David J Lederer Journal: Crit Care Med Date: 2017-06 Impact factor: 7.598
Authors: Angie Mae Rodday; Theresa Hahn; Anita J Kumar; Peter K Lindenauer; Jonathan W Friedberg; Andrew M Evens; Susan K Parsons Journal: Br J Haematol Date: 2020-02-23 Impact factor: 6.998
Authors: Jordan S Goldstein; Loretta J Nastoupil; Xuesong Han; Ahmedin Jemal; Elizabeth Ward; Christopher R Flowers Journal: Blood Date: 2018-07-24 Impact factor: 22.113
Authors: Nick Figura; Stella Flampouri; Nancy P Mendenhall; Christopher G Morris; Barry McCook; Savas Ozdemir; William Slayton; Eric Sandler; Bradford S Hoppe Journal: Adv Radiat Oncol Date: 2017-01-18
Authors: Shivanshu Awasthi; Travis Gerke; Vonetta L Williams; Francis Asamoah; Angelina K Fink; Rajesh Balkrishnan; Jong Y Park; Kosj Yamoah Journal: Cancer Control Date: 2019 Jan-Dec Impact factor: 3.302
Authors: Catherine Ireland; Eric Wiedower; Muhammad Mirza; Melissa Crawley; Alexandria Tran; George Yaghmour; Mike G Martin Journal: World J Oncol Date: 2018-05-01